Dr John Brown
Chairman

John Brown, PhD, MBA, FRSE, joined the Board of BTG in January 2008 and was appointed non-executive Chairman in March 2008. He is the Chairman of the Nomination Committee.

John is Chairman of Axis-Shield plc and a non-executive director of Vectura Group plc. He is Chairman of the Roslin Foundation and a non-executive director of the Technology Strategy Board. Until late 2003, John was Chief Executive of Acambis plc. He is a Fellow of the Royal Society of Edinburgh and an Honorary Professor of the University of Edinburgh.

Dr Louise Makin
Chief Executive Officer

Louise Makin joined BTG as Chief Executive Officer in October 2004 and she is a non-executive director of Premier Foods plc.

From 2001, she was President, Biopharmaceuticals Europe of Baxter Healthcare, where she was responsible for Europe, Africa and the Middle East. Louise joined Baxter Healthcare in 2000 as Vice President, Strategy & Business Development Europe. Before joining Baxter, she was Director of Global Ceramics at English China Clay and prior to that she held a variety of roles at ICI between 1985 and 1998. Louise has an MBA, and holds an MA in Natural Sciences and a PhD in Metallurgy from the University of Cambridge.

Rolf Soderstrom, BA, ACA, joined BTG as Chief Financial Officer in December 2008 from Protherics PLC, where he was Finance Director from August 2007.

From 2004, he was a Divisional Finance Director of Cobham plc, managing a portfolio of businesses across Europe and the USA. From 2000 he was a Director of Corporate Finance at Cable & Wireless plc. Prior to this, he worked in the Corporate Recovery and Corporate Finance Department of PricewaterhouseCoopers after qualifying as a Chartered Accountant.

Peter Chambré
Non-executive director

Peter Chambré joined BTG as a non-executive director in September 2006 and he is a member of the Nomination and Remuneration Committees. Peter is Chairman of both Axellia Pharmaceuticals AS and 7TM Pharma A/S. He is also a non-executive director of Spectris plc, the precision instrumentation and controls company.

Peter was Chief Executive Officer of Cambridge Antibody Technology Group plc from 2002 until its acquisition by AstraZeneca plc in 2006. Previously he was Chief Operating Officer of Celera Genomics Group and Chief Executive of Bespak plc.

Dr William Jenkins
Non-executive director

William Jenkins MA, Msc, MD, FRCP(E) joined BTG as a non-executive director in 2002 and is a member of the Audit and Remuneration Committees. He is also a non-executive director at Eurand N.V., Consort Medical plc. and Vaximm AG.

William was previously Head of Clinical Development & Regulatory Affairs for Novartis Pharma AG, having held the same position pre-merger from 1992 with CIBA-Geigy AG. From 1988 he was Head of Global Clinical Research at Glaxo. Since 1999 he has been a consultant to pharmaceutical companies and to investment companies in the life sciences sector. He gained MA and MD degrees from the University of Cambridge and his earlier career was in medical research at the Royal Postgraduate Medical School and later as a Senior Lecturer at the Royal Free Hospital, University of London.

Giles Kerr joined BTG as a non-executive director in October 2007 and is Chairman of the Audit Committee and a member of the Nomination and Remuneration Committees.

Giles is currently the Director of Finance with the University of Oxford, UK. He is also a Director of Victrex plc, Elan Corporation plc and Isis Innovation Ltd. Previously Giles was the Group Finance Director and Chief Financial Officer of Amersham plc, acquired by GE Healthcare in 2004. Prior to his role at Amersham, he was a partner with Arthur Andersen in the UK. He is a graduate of the University of York and a Fellow of the Institute of Chartered Accountants in England and Wales.

Ian F R Much
Non-executive director

Photo to come shortly.....

Jim O’Shea joined BTG as a non-executive director in April 2009 and he is a member of the Nomination and Remuneration Committees. He is a director of Surface Logix Inc and CombinatoRx Inc and is a former Chairman of the US National Pharmaceuticals Council.

From 2007 to 2008, he was Vice Chairman of Sepracor, Inc, where he was also President and Chief Operating Officer from 1999 to 2007. Previously Jim was Senior Vice President of Sales & Marketing and Medical Affairs for Zeneca Pharmaceuticals (US), a business unit of Zeneca Inc. While at Zeneca, he held several management positions of increasing responsibility in international sales and marketing in the US and the UK.